Is China Pharma Holdings, Inc. (CPHI) a Buy, Sell, or Hold?
AMEX : CPHI
China Pharma Holdings, Inc.
$1.71 USD
-$6.39 (-78.89%)
- Volume
- 13.61M
- Average Volume
- 2.41M
- Market Capitalization
- $5.43M
- P/E Ratio
- -2.06
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $19.19
- Year Low
- $0.38
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.28
Company Overview
AMEX
Zhilin Li
Drug Manufacturers - Specialty & Generic
Healthcare
CPHI
221
CN
USD
Liquidity Metrics
0.10
0.28
0.07
0.02
0.00
Sales & Valuation
$4.14M
1.36
0.20
40.41
0.03
Profitability
-$0.74
-$3.19M
-88.82%
-88.82%
-18.98%
-7.82%
P/E Metrics
-2.06
-0.17
-0.17
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-1.55
3/9
-$5.26M
$45.32M
$8.12M
-$3.45M
Key Metrics (TTM)
$6.89M
1.73
-5.34
0.28
-18.98%
-8.60%
-81.89%
4.19%
77 days
Company Executives
| Name | Title |
|---|---|
| Zhilin Li | President, Chief Executive Officer, Chairman & Interim Chief Financial Officer |
| Huang Na | BOD Secretary & IR Manager |
Poll Results
No votes yet today — be the first to share your view!
About China Pharma Holdings, Inc. (AMEX:CPHI) Stock
China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascu ... lar and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.
China Pharma Announces Pricing of $5 Million Registered Direct Offering
2026-07-22 09:25:00
HAIKOU, China, July 22, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that the pricing of its registered direct offering of 2.5 million shares of its common stock ("Common Shares"), at a purchase price of $2 per share. The gross proceeds from the offering will be $5 million, before deducting placement agent fees and other offering expenses.
China Pharma Holdings, Inc. Comments on Unusual Market Activity
2026-07-21 16:00:00
HAIKOU, China, July 21, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July 21, 2026, the NYSE American has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it issued this statement under Section 401(d) of the NYSE American Company Guide that it was not aware of any material corporate developments that would explain the recent market activity.
2026-07-15 12:12:00
HAIKOU, China, July 15, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July 10, 13, and 15, 2026, the NYSE American has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it is not aware of any material nonpublic information or business developments that have not been publicly disclosed that would account for the recent trading activity.
2026-05-14 08:56:00
HAIKOU, China, May 14, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on May 12 and 13, the NYSE American has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it is not aware of any material nonpublic information or business developments that have not been publicly disclosed that would account for the recent trading activity.
Frequently Asked Questions
-
What is the current China Pharma Holdings, Inc. (CPHI) stock price?
-
China Pharma Holdings, Inc.(AMEX:CPHI) stock price is $1.71 in the last trading session. During the trading session, CPHI stock reached the peak price of $19.19 while $0.38 was the lowest point it dropped to. The percentage change in CPHI stock occurred in the recent session was --78.89% while the dollar amount for the price change in CPHI stock was -$6.39.
-
CPHI's industry and sector of operation?
-
The AMEX listed CPHI is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of CPHI?
-
Zhilin Li | President, Chief Executive Officer, Chairman & Interim Chief Financial Officer
Huang Na | BOD Secretary & IR Manager
|
|
| -
How many employees does CPHI have?
-
Number of CPHI employees currently stands at 221. CPHI operates from No. 17, Jinpan Road, Haikou, HA 570216, CN.
-
Link for CPHI official website?
-
Official Website of CPHI is: https://www.chinapharmaholdings.com
-
How do I contact CPHI?
-
CPHI could be contacted at phone #86 89 8668 11730 and can also be accessed through its website. CPHI operates from No. 17, Jinpan Road, Haikou, HA 570216, CN.
-
How many shares of CPHI are traded daily?
-
The average number of CPHI shares traded daily for last 3 months was 2.41M.
-
What is the market cap of CPHI currently?
-
The market value of CPHI currently stands at $5.43M with its latest stock price at $1.71